Abstract:Abstract Previous genetic studies of venous thromboembolism (VTE) have been largely limited to common variants, leaving the genetic determinants relatively incomplete. We performed an exome-wide association study of VTE among 14,723 cases and 334,315 controls. Fourteen known and four novel genes ( SRSF6 , PHPT1 , CGN , and MAP3K2 ) were identified through protein-coding variants, with broad replication in the FinnGen cohort. Most genes we discovered exhibited the potential to predict future VTE events in longitudinal analysis. Notably, we provide evidence for the additive contribution of rare coding variants to known genome-wide polygenic risk in shaping VTE risk. The identified genes were enriched in pathways affecting coagulation and platelet activation, along with liver-specific expression. The pleiotropic effects of these genes indicated the potential involvement of coagulation factors, blood cell traits, liver function, and immunometabolic processes in VTE pathogenesis. In conclusion, our study unveils the valuable contribution of protein-coding variants in VTE etiology and sheds new light on its risk stratification.

What problem does this paper attempt to address?

This paper aims to address the incomplete genetic determinants of venous thromboembolism (VTE). Specifically, previous genetic studies on VTE mainly focused on common variants, while relatively few studies were conducted on rare coding variants. Therefore, this study explored the role of rare coding variants in VTE through whole - exome association analysis and attempted to identify new VTE - related genes. ### Research Background - **Public Health Challenges of VTE**: VTE is a serious global public health problem, including deep - vein thrombosis (DVT) and pulmonary embolism (PE), with high morbidity and mortality. - **Importance of Genetic Factors**: VTE is a multifactorial disease, involving the interaction of environmental and genetic factors. Genetic factors have a great impact on VTE. Twin studies estimate its heritability to be more than 40%. - **Limitations of Existing Studies**: Existing genetic studies mainly focused on common variants (MAF > 1%), while fewer studies were conducted on rare variants, although these rare variants may have a greater biological effect on VTE. ### Research Methods - **Sample Selection**: The study used data from 349,038 participants in the UK Biobank, including 14,723 VTE cases and 334,315 controls. - **Whole - Exome Sequencing Analysis**: By analyzing whole - exome sequencing data, the research team tested the association between rare coding variants and VTE. - **Gene - level Collapse Analysis**: The study adopted a collapse analysis of 20,629 genes in 12 different models to evaluate the impact of rare coding variants on VTE. ### Main Findings - **Known and Newly Discovered Genes**: The study found 14 known and 4 new VTE - related genes (such as SRSF6, PHPT1, CGN and MAP3K2). - **Longitudinal Analysis**: These genes also showed predictive ability for future VTE events in longitudinal analysis. - **Gene Function Enrichment**: These genes are enriched in the coagulation cascade and platelet activation pathways and are mainly expressed in the liver. - **Pleiotropic Effects**: These genes also show pleiotropic effects, indicating that coagulation factors, blood cell characteristics, liver function and immunometabolic processes may play important roles in the pathogenesis of VTE. - **Interaction between Rare and Common Variants**: The study also revealed the pleiotropic effects of rare coding variants and common variants, indicating that they have complementary roles in VTE risk stratification. ### Conclusion This study, through whole - exome association analysis, revealed the important contribution of rare coding variants in VTE genetics, providing new insights into VTE risk stratification. These findings not only help to understand the pathogenesis of VTE, but also provide a scientific basis for future prevention and treatment strategies.

Genetic associations of protein-coding variants in venous thromboembolism

Genome-wide Association Analysis of Venous Thromboembolism Identifies New Risk Loci and Genetic Overlap with Arterial Vascular Disease

Relationship Between Endothelial Cell Protein C Receptor Gene 6936A/G Polymorphisms and Deep Venous Thrombosis.

Exome Sequencing Identifies Novel Genetic Variants Associated with Varicose Veins

Whole Exome Sequencing Identifies Genetic Variants in Chinese Han Pregnant Women with Venous Thromboembolism-a Case Control Study

Whole exome sequencing identifies genetic variants in Chinese Han pregnant women with venous thromboembolism

Identifying mutation‐driven changes in gene functionality that lead to venous thromboembolism

Common genetic risk factors for venous thrombosis in the Chinese population

Whole Genome Analysis of Venous Thromboembolism: the Trans-Omics for Precision Medicine Program

Genome-wide cross-trait analysis and Mendelian randomization reveal a shared genetic etiology and causality between COVID-19 and venous thromboembolism

Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease

A genome-wide association study for varicose veins

Shared genetic etiology of vessel diseases: A genome-wide multi-traits association analysis

Genetic Insights through Chinese VTE Pedigree Interpretation Using the ACMG Method: Unraveling Potencial Genetic Risk Factors

Potential causal relationships between blood metabolites, inflammatory cytokines, and venous thromboembolism

Identifying potential drug targets for varicose veins through integration of GWAS and eQTL summary data

Venous thromboembolism and severe COVID-19: a Mendelian randomization trial and transcriptomic analysis

Combined Effects of Thrombosis Pathway Gene Variants Predict Cardiovascular Events

Construction and optimization of a polygenic risk model for venous thromboembolism in the Chinese population

Recent progress of gene polymorphisms in the formation of venous thromboembolism in different ethnic groups

Genetic Analysis Implicates LDL Cholesterol Reduction and Plasminogen Activator-inhibitor 1 Antagonism as Therapeutic Interventions for Venous Thromboembolism